TY - JOUR
T1 - Platelet Microvesicles, Inflammation, and Coagulation Markers
T2 - A Pilot Study
AU - Gidaro, Antonio
AU - Delitala, Alessandro Palmerio
AU - Manetti, Roberto
AU - Caccia, Sonia
AU - Soloski, Mark J.
AU - Lambertenghi Deliliers, Giorgio
AU - Castro, Dante
AU - Donadoni, Mattia
AU - Bartoli, Arianna
AU - Sanna, Giuseppe
AU - Bergamaschini, Luigi
AU - Castelli, Roberto
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/12
Y1 - 2023/12
N2 - Background: Platelet “Microvesicles” (MVs) are studied for their role in blood coagulation and inflammation. The study aimed to establish if MVs are related to age, plasma levels of inflammation, coagulation, and fibrinolysis markers in healthy individuals. Methods: We prospectively enrolled volunteers aged over 18 years. MVs, plasma levels of C-reactive protein (CRP), Interleukin 6 (IL-6), Interleukin 10 (IL-10), Interleukin 17 (IL-17), and transforming growth factor β (TGF-β), fibrinogen, plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (VWF), homocysteine, factor VII (FVII), thrombin activatable fibrinolysis inhibitor (TAFI), and Protein S were tested. Results: A total of 246 individuals (median age 65 years (“IQR”54–72)) were evaluated. Both univariate analysis and logistic regression models showed that MVs positively correlate with age, CRP, IL-6, IL-10, IL-17, TGF-β, fibrinogen, PAI-1, VWF, FVII, and homocysteine, while inversely correlating with TAFI and Protein S. The ROC curve analysis performed to identify a cut off for MV values (700 kMP) showed a good accuracy with over-range cytokines fibrinolysis factor and coagulation markers. Conclusions: To the best of our knowledge, this study is the first to correlate MVs with an entire panel of cardiovascular risk factors in healthy individuals. A future possible role of MVs in screening exams is suggested.
AB - Background: Platelet “Microvesicles” (MVs) are studied for their role in blood coagulation and inflammation. The study aimed to establish if MVs are related to age, plasma levels of inflammation, coagulation, and fibrinolysis markers in healthy individuals. Methods: We prospectively enrolled volunteers aged over 18 years. MVs, plasma levels of C-reactive protein (CRP), Interleukin 6 (IL-6), Interleukin 10 (IL-10), Interleukin 17 (IL-17), and transforming growth factor β (TGF-β), fibrinogen, plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (VWF), homocysteine, factor VII (FVII), thrombin activatable fibrinolysis inhibitor (TAFI), and Protein S were tested. Results: A total of 246 individuals (median age 65 years (“IQR”54–72)) were evaluated. Both univariate analysis and logistic regression models showed that MVs positively correlate with age, CRP, IL-6, IL-10, IL-17, TGF-β, fibrinogen, PAI-1, VWF, FVII, and homocysteine, while inversely correlating with TAFI and Protein S. The ROC curve analysis performed to identify a cut off for MV values (700 kMP) showed a good accuracy with over-range cytokines fibrinolysis factor and coagulation markers. Conclusions: To the best of our knowledge, this study is the first to correlate MVs with an entire panel of cardiovascular risk factors in healthy individuals. A future possible role of MVs in screening exams is suggested.
KW - C-reactive protein (CRP)
KW - Interleukin 10 (IL-10)
KW - Interleukin 17 (IL-17)
KW - Interleukin 6 (IL-6)
KW - Protein S
KW - factor VII (FVII)
KW - fibrinogen
KW - homocysteine
KW - microparticles
KW - microvesicles
KW - plasminogen activator inhibitor-1 (PAI-1)
KW - thrombin activatable fibrinolysis inhibitor (TAFI)
KW - transforming growth factor β (TGF-β)
KW - von Willebrand factor (VWF)
UR - http://www.scopus.com/inward/record.url?scp=85180677016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85180677016&partnerID=8YFLogxK
U2 - 10.3390/hematolrep15040069
DO - 10.3390/hematolrep15040069
M3 - Article
C2 - 38132277
AN - SCOPUS:85180677016
SN - 2038-8322
VL - 15
SP - 684
EP - 695
JO - Hematology Reports
JF - Hematology Reports
IS - 4
ER -